A research team led by Rice University’s Yang Gao has uncovered new insights into the molecular mechanisms of ADAR1, a ...

RNAs are an incredibly valuable but severely underexploited class of drug ... in RNA-targeted small-molecule drug design and development. Azor has developed AI and physics-based computational ...

After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based ...

RNA-based medicines are one of the most promising ways to fight human disease, as demonstrated by the recent successes of RNA vaccines and double-stranded RNA (dsRNA) therapies. But while health care ...

RNA molecules are ... for the development of RNA-based therapeutics" says Höbartner. "It is conceivable that further developed ribozymes could one day be used as drugs themselves." ...

Biogen has made a further push into RNA-based drug discovery via a collaboration with Envisagenics, which applies artificial intelligence RNA sequencing data to discover new drug targets and ...

The failures of ophthalmology drug development ... company's RNA-based therapy for Dravet syndrome is not just another seizure treatment but a potential breakthrough in disease modification ...

Vice President RNA Formulation & Drug Delivery, BioNTech RNA Pharmaceuticals Development of Formulations for Delivery of RNA and Small Molecules Shalini Andersson, Senior Director and Head of New ...

“But this is just a proof-of-concept study. By tweaking the nanoparticle composition, we could deliver other RNA-based drugs to different organs. There’s a saying: “’’It’s all in the ...

Alnylam Pharmaceuticals has developed GalNAc conjugates such as Amvuttra (vutrisiran), which enable targeted delivery of RNA-based drugs specifically to liver cells. Similarly, Arrowhead ...